Eli Lilly Acquires 4E Therapeutics to Expand Pain Pipeline

Eli Lilly has acquired Austin-based 4E Therapeutics, adding a nonaddictive chronic-pain program to its broader effort to build beyond its blockbuster GLP-1 business. The companies did not disclose financial terms.

The deal gives Lilly another shot at the pain market after earlier programs in the area stalled or failed to advance. 4E is a neuroscience biotech focused on chronic pain, and its pipeline includes oral MNK inhibitors, a class being developed as a non-opioid pain treatment.

What 4E Brings

According to the reporting, 4E Therapeutics has been working on treatments aimed at chronic pain without the addictive profile associated with opioids. Lilly is adding that work to a pipeline that already includes other pain bets.

Barron’s noted that Lilly bought SiteOne Therapeutics in 2025 for $1 billion, gaining rights to the experimental non-opioid pain drug STC-004. The new acquisition suggests Lilly is still willing to keep investing in the category even after previous setbacks.

Why Lilly Wants It

The acquisition fits Lilly’s effort to diversify its pipeline while it leans on strong demand for its obesity and diabetes drugs. Pain remains a difficult but potentially large market, and a successful non-opioid therapy would give Lilly another major franchise outside GLP-1s.

4E co-founder Joe Price said Lilly’s development, translational and commercial capabilities made it the right home for the work, according to Dow Jones reporting.

What Is Unknown

The biggest unanswered question is value: the companies did not disclose what Lilly paid. There is also no public timeline yet for development milestones or trial updates tied to 4E’s MNK inhibitor program.

Lilly has not said whether it will keep 4E’s Austin operation intact or outline any integration plans. Those details will determine how quickly the deal becomes visible inside Lilly’s broader pain strategy.